AI assistant
Dr. Lal Pathlabs Limited Earnings Release 2019
61783_rns_2019-02-08_d7d7f5f9-a11e-460e-a29c-0f985e59f08b.pdf
Earnings Release
Open in viewerOpens in your device viewer
February 8,201 9
The National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E) Mumbai - 400051
The Bombay Stock Exchange Limited 15" Floor, Phiroze Jeejeeboy Towers Dalal Street, Mumbai - 400001
Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended December 31,2018
Dear SirIMadam,
Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended December 31,2018.
You are requested to take note of the above.
Thanking You,
Yours Faithfully,
For Dr. Lal PathLabs Limited
Rajat Kalra Company Secretary & Legal Head
Encl: As above
For Immediate Release February 8, 2019
Dr. Lal PathLabs Limited records revenue growth of 11.3% to Rs 2,925 mn in Q3 FY2018-19
New Delhi, India, Feb 8, 2019 – Dr. Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2018
Consolidated Performance Highlights: Q3FY2018-19 vs Q3FY2017-18 Revenue growth: 11.3% at Rs 2,925 mn, Normalised EBITDA at Rs 706 mn, PBT at Rs 679 mn Normalised EBITDA margins at 24.1% vs 23.1% last year and PAT Rs 461 mn with margin at 15.8%
- Operating Revenue increased by 11.3% in Q3 to Rs. 2,925 million vs Rs 2,627 million in the previous year same quarter. Underlying volume growth is 12.1% during the quarter.
- Normalised EBITDA in Q3FY19 grew 16.3% to Rs.706 million from Rs 607 million in the same quarter last year, after adjustment for stock based compensation costs and CSR expense.
- Normalised EBITDA Margin at 24.1% for Q3 FY19 vs 23.1% in Q3 FY18.
- PBT is at Rs 679 mn in Q3 vs Rs 555 mn in Q3 last year.
- Profit after Tax in Q3FY19 at Rs. 461 million as compared to Rs 363 million in Q3 last year.
Financial Overview (Consolidated) in Rs mn
| Particulars | Q3 FY19 | Q3 FY18 | Growth% | YTDDec' 18 | YTDDec' 17 | Growth% |
|---|---|---|---|---|---|---|
| Total Revenue | 2,925 | 2,627 | 11.3% | 9,023 | 7,901 | 14.2% |
| Total Expenditure | 2,269 | 2,061 | 6,749 | 5,901 | ||
| EBITDA | 656 | 566 | 15.9% | 2,274 | 2,000 | 13.7% |
| Adj for Stock based comp. & CSRcost | 50 | 41 | 130 | 95 | ||
| Normalised EBITDA | 706 | 607 | 16.3% | 2,404 | 2,095 | 14.7% |
| Normalised Margins | 24.1% | 23.1% | 26.6% | 26.5% | ||
| Other income incl. interest | 122 | 71 | 325 | 223 | ||
| PBT | 679 | 555 | 22.3% | 2,314 | 1,993 | 16.1% |
| Margins | 23.2% | 21.1% | 25.6% | 25.2% | ||
| PAT | 461 | 363 | 27.0% | 1,531 | 1,315 | 16.4% |
| Margins | 15.8% | 13.8% | 17.0% | 16.6% | ||
| EPS (Basic) | 5.56 | 4.39 | 26.7% | 18.48 | 15.97 | 15.7% |
| EPS (Diluted) | 5.55 | 4.39 | 26.4% | 18.45 | 15.95 | 15.7% |
Dr. Lal Pathlabs Limited 12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com 1
About Dr. Lal PathLabs Limited
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Dr. Lal PathLabs has built a national, "hub and spoke" network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 191 other clinical laboratories, 2153 patient service centers and 5,624 pickup points as of March 31, 2018. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.
Contact Details
Ved Prakash Goel Chief Financial Officer Dr. Lal PathLabs Limited
+91 124 3016500 [email protected]
Aparna Agarwal Adfactors PR
+91 9811177405 [email protected]
For further information on Dr. Lal PathLabs see www.lalpathlabs.com
Safe Harbour
This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.
Dr. Lal Pathlabs Limited
12th Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com 2